Abstract
In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1–4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5–8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1–4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug’s tumoricidal action on 8505C cell line.
Keywords: Apoptosis, autophagy, caspase, cisplatin, iridium(III) complexes, ruthenium(II) complexes.
Anti-Cancer Agents in Medicinal Chemistry
Title:Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes
Volume: 16 Issue: 11
Author(s): Gerd Ludwig, Marija Mojić, Mirna Bulatović, Sanja Mijatović, Danijela Maksimović-Ivanić, Dirk Steinborn and Goran N. Kaluđerović
Affiliation:
Keywords: Apoptosis, autophagy, caspase, cisplatin, iridium(III) complexes, ruthenium(II) complexes.
Abstract: In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1–4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5–8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1–4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug’s tumoricidal action on 8505C cell line.
Export Options
About this article
Cite this article as:
Ludwig Gerd, Mojić Marija, Bulatović Mirna, Mijatović Sanja, Maksimović-Ivanić Danijela, Steinborn Dirk and Kaluđerović N. Goran, Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (11) . https://dx.doi.org/10.2174/1871520615666151029100749
DOI https://dx.doi.org/10.2174/1871520615666151029100749 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Application of Sorafenib for Treating Hepatocellular Carcinoma and Beyond
Clinical Cancer Drugs New Paradigms in Cellular Function and the Need for Top-Down Proteomics Analysis
Current Proteomics Comparison of Radiohaloanalogues of Meta-Iodobenzylguanidine (MIBG) for a Combined Gene- and Targeted Radiotherapy Approach to Bladder Carcinoma
Medicinal Chemistry Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials HPA Axis Function During the Perinatal Period in Patients with Affective Disorders
Current Psychiatry Reviews Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
Current Drug Targets Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy Defensins: Key Molecules in Ocular Surface Protection
Current Immunology Reviews (Discontinued) New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets Analytical Tools for Detecting Amyloid Beta Oligomerisation and Assembly
Current Pharmaceutical Analysis The Potential Role of Claudins in Regulation of Metastasis and Development of Drug Resistance in Breast Cancer
Clinical Cancer Drugs Development of WT1 Peptide Cancer Vaccine Against Hematopoietic Malignancies and Solid Cancers
Current Medicinal Chemistry Non-coding RNAs as Novel Biomarkers in Cancer Drug Resistance
Current Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences The Role of Androgen Receptor Mutations in Prostate Cancer Progression
Current Genomics The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Family of Proteins: Transcriptional Modifiers with Multi-Functional Protein Interfaces
Current Molecular Medicine Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway
Current Cancer Drug Targets